Robot-assisted colon resection remains technically feasible across multiple platforms, though recent data indicates performance variations between the Da Vinci, Hugo RAS, and Versius systems. In a prospective study of 45 patients conducted between February and December 2024, researchers found that while all three platforms successfully performed colorectal surgeries, the systems differed in operating room efficiency and the need for manual intervention, according to the COMPAR-CRC trial published in Laparoscopic, Endoscopic and Robotic Surgery.
How do the three robotic platforms compare in the operating room?
The study, led by C. Pedrazzani and colleagues, tracked 15 procedures for each of the three robotic systems. The Da Vinci Xi system reported zero conversions to traditional laparoscopy or open surgery. In contrast, researchers recorded two conversions with the Hugo RAS platform and three with the Versius system. The authors noted that while clinical outcomes remained similar across all groups, the operational demands varied significantly.
Efficiency metrics also diverged. The Hugo RAS platform was associated with longer total operating room times and larger incision lengths compared to the other systems. Meanwhile, the Versius platform required surgeons to rely more frequently on external laparoscopic energy devices to complete the procedures, a statistically significant difference (p < 0.001) highlighted in the study findings.
What are the implications for colorectal cancer surgery?
Surgeons performed these procedures primarily to treat colon cancer, which accounted for 68.9% of the cases in the study. Despite the variations in equipment performance, the researchers found no significant differences in post-operative recovery times or long-term oncological results. This suggests that for experienced surgeons, the choice of platform did not fundamentally alter the oncological efficacy of the resection.
However, the data points to a learning curve and equipment-specific requirements that could influence hospital procurement decisions. One intra-operative instrument malfunction occurred with the Hugo RAS, while one surgical complication was reported across each of the three groups. These findings emphasize that surgical expertise remains the primary driver of patient safety, regardless of the robotic interface used.
Why are larger comparative trials necessary?
While the initial results are encouraging, the study authors emphasize that these findings are exploratory. A sample size of 45 patients is insufficient to draw definitive conclusions about the long-term superiority of one system over another. Future research must expand to larger patient cohorts to determine if the differences in operating time and device usage translate into tangible impacts on patient recovery or health system costs.
The full COMPAR-CRC study serves as a baseline for hospitals transitioning to multi-platform robotic surgery environments. As more European surgical units adopt diverse robotic tools, standardizing metrics for “success”—beyond just feasibility—will become a priority for clinical boards.
Frequently Asked Questions
Are all robotic surgical platforms equally effective?
According to the Pedrazzani et al. study, all three platforms are feasible for colon resection. While technical differences exist in operating room time and equipment usage, there were no significant differences in oncological outcomes.
Did the type of robot affect patient recovery?
No. The study found no significant differences in post-operative recovery between patients treated with the Da Vinci, Hugo RAS, or Versius systems.
Why were there conversions to open surgery?
Conversions occurred in the Hugo RAS and Versius groups, though the study attributes these to the nature of the exploratory trial and the learning process involved with newer platforms.
Have you or a family member undergone robot-assisted surgery? Share your experiences in the comments below or subscribe to our medical technology newsletter for the latest updates on surgical innovation.
